Acute Hepatitis Due to Agomelatine Use in Elderly Women with Depression: Case Series
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Although agomelatine may be associated with an increased risk of hepatotoxicity, the incidence rate of acute hepatitis seemed divergent between clinical trials and daily practice. Whether aging or gender is a risk factor in developing hepatotoxicity due to agomelatine is not clear. We present 3 older female cases with acute hepatitis occurring due to highly probable idiosyncratic drug-induced liver injury caused by agomelatine. From these cases, regular surveillance on liver function in the older women taking antidepressants would be of benefits.
Abstract
Although agomelatine may be associated with an increased risk of hepatotoxicity, the incidence rate of acute hepatitis seemed divergent between clinical trials and daily practice. Whether aging or gender is a risk factor in developing hepatotoxicity due to agomelatine is not clear. We present 3 older female cases with acute hepatitis occurring due to highly probable idiosyncratic drug-induced liver injury caused by agomelatine. From these cases, regular surveillance on liver function in the older women taking antidepressants would be of benefits.
참고문헌 (11)
- Billioti de Gage S, "Antidepressants and hepatotoxicity : a cohort study among 5 million individuals registered in the French national health insurance database", CNS Drugs, 32, pp.673~684 (2018)
- Voican CS, "Antidepressantinduced liver injury : a review for clinicians", Am J Psychiatry, 171, pp.404~415 (2014)
- Sheng Min Wang, "Agomelatine for the Treatment of Generalized Anxiety Disorder: A Meta-Analysis", Clinical Psychopharmacology and Neuroscience, 18(3), pp.423~433 (2020), 대한정신약물학회[DOI]
- Gahr M, "Hepatotoxicity associated with agomelatine and other antidepressants : disproportionality analysis using pooled pharmacovigilance data from the Uppsala Monitoring Centre", J Clin Pharmacol, 55, pp.768~773 (2015)
- Gahr M, "Agomelatine and hepatotoxicity : implications of cumulated data derived from spontaneous reports of adverse drug reactions", Pharmacopsychiatry, 46, pp.214~220 (2013)
- Buoli M, "Pharmacokinetic evaluation of agomelatine for the treatment of generalised anxiety disorder", Expert Opin Drug Metab Toxicol, 10, pp.885~892 (2014)
- Laux G, "Pooled analysis of four non-interventional studies : effectiveness and tolerability of the antidepressant agomelatine in daily practice", Adv Ther, 34, pp.895~914 (2017)
- "Gastroenterol Hepatol", 2014, 92~94
- Pladevall-Vila M, "Risk of acute liver injury in agomelatine and other antidepressant users in four European countries : a cohort and nested case-control study using automated health data sources", CNS Drugs, 33, pp.383~395 (2019)
- Esma Akpınar, "Agomelatine versus Sertraline: An Observational, Open-labeled and 12 Weeks Follow-up Study on Efficacy and Tolerability", Clinical Psychopharmacology and Neuroscience, 14(4), pp.351~356 (2016), 대한정신약물학회
- Pariente A, "Impact of safety alerts on measures of disproportionality in spontaneous reporting databases : the notoriety bias", Drug Saf, 30, pp.891~898 (2007)